News

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy...

Researchers at The University of Alabama at Birmingham are recruiting for a phase 2 clinical trial designed to offer an innovative treatment...

Presented by Dr Ian Morison on 1 August, 2018 Watch the video below

Patients with myeloma with outpatient prescription drug coverage were more likely to receive oral targeted agents instead of parenteral...

Clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic combination among patients with multiple myeloma (MM),...

A $2 million phase 2 Small Business Technology Transfer (STTR) grant to optimize a promising new compound that has shown efficacy in preclinical...

An independent body that offers guidance to improve health and social care in England recommended against the use of axicabtagene ciloleucel, one of...

There may be a way to detect multiple myeloma (MM) earlier — effectively shortening the longer diagnostic interval that is typically associated with...

The deep and durable phase I responses seen with the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with...

The European Commission has approved the use of Novartis’s tisagenlecleucel (Kymriah) and Gilead’s axicabtagene ciloleucel (Yescarta), two chimeric...

When practicing precision oncology for multiple myeloma, clinicians currently match specific DNA mutations to the optimal targeted therapy. However,...